Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin or Alpha Lipoic Acid with Metformin in PCOS
NCT07182526Phase 2Recruiting
- Sponsor
- Al-Mustansiriyah University
- Start
- Sep 2025
- Primary completion
- May 2026
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of quercetin and alpha-lipoic acid in polycystic ovary syndrome (PCOS) (3 arms), sponsored by Al-Mustansiriyah University. Primary endpoints: Change in Hormonal Profile (LH, FSH, Testosterone) at 3 months and Change in Glycemic Control Markers (Fasting Glucose, Insulin, HOMA-IR) at 3 months. Started Sep 2025; status: recruiting.
02
Drugs
quercetinalpha-lipoic acid
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT07182526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182526.